Professor Giunti and her team have identified a potential biomarker for FA by investigating the eye problems commonly found in patients.
The eyes might be the windows to disease progression in FA Read More »
Leading gene therapy company uniQure have announced preclinical data on its gene therapy candidate, AMT-150, for the treatment of Spinocerebellar Ataxia 3 (SCA3).
uniQure releases new data from Spinocerebellar Ataxia Type 3 gene therapy study Read More »
A mutation in gene found to be responsible for CANVAS, a specific form of late onset ataxia, is likely to also be responsible for forms of late onset ataxia with unknown causes.
Mutation in RFC1 gene is likely to be common cause of late-onset ataxia Read More »
A group of researchers from Germany have found that real-time audio bio-feedback improves stability in degenerative cerebellar ataxia.
A recently published study has demonstrated that intensive home-based speech therapy can improve dysarthria (difficulty speaking) in autosomal recessive spastic ataxia Charlevoix-Saguenay (ARSACS).
The AMRC Impact Report highlights the concrete ways that medical research charities make a difference to people and society through the research they fund
AMRC Impact Report Read More »
The ‘New Modalities Ecosystem’, launched in 2018 by the Finnish pharmaceutical company Orion, aims to exploit Finnish expertise to deliver new treatments and technologies for rare diseases.
New initiative for rare diseases launched by Finnish pharmaceutical company Read More »
The ongoing European Friedreich’s Ataxia Consortium for Translational Studies (EFACTS) study, part-funded by Ataxia UK has released a report evaluating the clinical variability in Friedreich’s ataxia (FA) symptoms.
EFACTS reports most common ‘non-ataxia’ symptoms in FA Read More »
A recent study investigating the effect of investigating the effect of physiotherapy on patients with spinocerebellar ataxia type 7 (SCA7) has found that it to significantly improve symptoms.
Effects of physiotherapy in patients with spinocerebellar ataxia type 7 Read More »
Ataxia UK’s Head of Research Julie Greenfield reports on the 2018 Euro-ataxia annual conference held in Frankfurt.
Euro-ataxia annual meeting Read More »
Experiments in the laboratory using skin cells taken from people with Friedreich’s ataxia have shown that these cells may be more susceptible to damage caused by certain sun rays.
Friedreich’s ataxia may cause greater susceptibility to skin damage by UVA rays Read More »
Ataxia UK has been talking with Minoryx Therapeutics, a company focusing on developing new drugs for rare conditions, and we are delighted with this new trial being announced.
We are delighted that on 20 February 2019 the Ataxia UK Medical Guidelines were published in the Orphanet Journal of Rare Diseases.
Ataxia UK medical guidelines published in peer-reviewed journal Read More »
A study has found that a rapid, non-invasive eye exam could potentially be used as a tool for assessing Friedreich’s ataxia patients and as a biomarker in clinical trials.
Non-invasive eye exam found to predict disease severity in Friedreich’s ataxia Read More »
Biopharmaceutical company, IntraBio, has received an Orphan Drug Designation from the US Food and Drug Administration (FDA) for its lead compound (IB1000) for the treatment of spinocerebellar ataxias (SCA).
FDA oprphan drug designation for spinocerebellar ataxia Read More »
Researchers at the University of Florida have been granted $450,000 by Italian patient advocacy group GoFAR towards a gene therapy project for Friedreich’s ataxia (FA).
The UK government has committed to ensuring the UK is as closely aligned as possible with the new EU Clinical Trials Regulation (CTR).
An imaging technique called Optical Coherence Tomography (OCT) may help with early diagnosis of Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS).
New method for diagnosing ARSACS discovered at Specialist Ataxia Centre in London Read More »
Studies have shown that the frataxin gene may be activated by a wide variety of synthetic antisense oligonucleotides
New options for targeting gene mutation in FA described in nucleic acid therapeutics Read More »
Pharmaceutical company, Reata, has announced new preclinical data that supports the potential use of omaveloxolone in Friedreich’s ataxia.
Positive results announced for potential FA treatment Read More »
Ataxia UK attended conferences in Birmingham and St Asaph to and give talks about ataxia to health and social care professionals.
Raising awareness and understanding of ataxia among healthcare professionals Read More »
Results from a phase 2 clinical trial suggest that a new therapy may improve neurological function and prevent disease progression relative to the natural course of Friedreich’s ataxia (FA).
Omaveloxolone has recently been given an Orphan drug designation for Friedreich’s ataxia the European Medicines Agency.
New EU Orphan drug designation for Freidreich’s ataxia Read More »
A new placebo-controlled trail in humans, testing a novel therapy, Tak-831 for Friedreich’s ataxia, has begun in America.
Results of a study evaluating TAK-831 in adults with Friedreich’s ataxia (FA) Read More »
The results of the patient communications survey conducted at the 2018 Ataxia UK conference were presented in London by Ataxia UK partners Costello Medical.
Results presented from patient communications survey Read More »
Results from MOXIe study reveal potential therapy for Friedreich’s ataxia, omaveloxolone, is well tolerated.
Results published from part 1 of Friedreich’s ataxia drug trial Read More »
UK researchers guaranteed funding until the end of 2020 from EU programmes even in the event of a no-deal Brexit.
Results from a study conducted at the London Ataxia Centre have shown that 3 proteins which may represent new biomarkers in Friedreich’s ataxia (FA).
Study discovers 3 potential blood based biomarkers for FA Read More »
The AMRC has released their expenditure statistics for 2018.
AMRC releases annual research expenditure statistics Read More »
Euro-ataxia held the latest annual meeting on 9-10th November 2018 in Frankfurt, Germany, hosted by the German ataxia charity DHAG, organised by Ataxia UK and sponsored by BioMarin.
Euro-ataxia conference 2018 Read More »
